Open access
Aug 2026
Suppression of EGFR signaling and drug-induced potentiation are widespread features of oncogenic RTK fusions.
It is uncovered that a large number of RTK fusions simultaneously act as both activators and suppressors of signaling, the mechanisms of which could be exploited for biomimetic therapies that enhance cell killing and suppress drug tolerance.
Yu-Zhi Gao, D. Gonzalez-Martinez, Sofia Wissert et al.
· Proceedings of the National... · 0 citations